| Literature DB >> 32243484 |
Tzu-Chun Chung1,2, Tzu-Shan Chen3,4, Yao-Chun Hsu5,6,7, Feng-Chen Kao1,2,8, Yuan-Kun Tu1,2, Pao-Hsin Liu9.
Abstract
BACKGROUND/Entities:
Year: 2020 PMID: 32243484 PMCID: PMC7122785 DOI: 10.1371/journal.pone.0231092
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow chart.
Comparison of demographic and clinical characteristics of the 4 groups.
| Normal (n = 664,349) | Acetabular fracture (n = 3,041) | Pelvic fracture (n = 5,618) | acetabular and pelvic fracture (n = 733) | P value | |||||
|---|---|---|---|---|---|---|---|---|---|
| Age | 41.86 ± 15.98 | 41.84 ± 14.90 | 42.79 ± 16.11 | 42.76 ± 15.07 | <0.0001 | ||||
| Gender (Male) (%) | 338921 (51.02) | 2441 (80.59) | 3532 (63.34) | 498 (68.5) | <0.0001 | ||||
| CCI | 0.09 ± 0.51 | 0.64 ± 1.45 | 0.76 ± 1.64 | 0.73 ± 1.45 | <0.0001 | ||||
| Comorbidities | |||||||||
| Myocardial infarct | 545 (0.08) | 17 (0.56) | 37 (0.66) | 1 (0.14) | <0.0001 | ||||
| Congestive heart failure | 1728 (0.26) | 66 (2.17) | 102 (1.82) | 10 (1.36) | <0.0001 | ||||
| Peripheral vascular disease | 493 (0.07) | 33 (1.09) | 87 (1.55) | 10 (1.36) | <0.0001 | ||||
| Cerebrovascular disease | 4478 (0.67) | 90 (2.96) | 246 (4.38) | 26 (3.55) | <0.0001 | ||||
| Dementia | 315 (0.05) | 24 (0.79) | 55 (0.98) | 3 (0.41) | <0.0001 | ||||
| Chronic lung disease | 3227 (0.49) | 147 (4.83) | 262 (4.66) | 30 (4.09) | <0.0001 | ||||
| Connective tissue disease | 461 (0.07) | 26 (0.85) | 87 (1.55) | 12 (1.64) | <0.0001 | ||||
| Ulcer | 6343 (0.95) | 366 (12.04) | 851 (15.15) | 115 (15.69) | <0.0001 | ||||
| Chronic liver disease | 3037 (0.46) | 231 (7.6) | 444 (7.9) | 77 (10.5) | <0.0001 | ||||
| Diabetes | 20302 (3.06) | 288 (9.47) | 499 (8.88) | 79 (10.78) | <0.0001 | ||||
| Diabetes with end organ damage | 1351 (0.2) | 56 (1.84) | 106 (1.89) | 12 (1.64) | <0.0001 | ||||
| Hemiplegia | 812 (0.12) | 29 (0.95) | 92 (1.64) | 7 (0.95) | <0.0001 | ||||
| Moderate or severe kidney disease | 3289 (0.5) | 140 (4.6) | 288 (5.13) | 45 (6.14) | <0.0001 | ||||
| Malignant tumor | 2650 (0.4) | 45 (1.48) | 133 (2.37) | 10 (1.36) | <0.0001 | ||||
| Leukemia, lymphoma | 155 (0.02) | 3 (0.1) | 4 (0.07) | 1 (0.14) | 0.0011 | ||||
| Moderate or severe liver disease | 375 (0.06) | 5 (0.16) | 30 (0.53) | 2 (0.27) | <0.0001 | ||||
| Metastasis | 611 (0.09) | 16 (0.53) | 40 (0.71) | 2 (0.27) | <0.0001 | ||||
| AIDS | - | - | - | - | - | ||||
Comparison of numbers (%) and risk of hip arthroplasty between different 4 fracture group groups and normal group.
| Normal | Acetabular fracture | Pelvic fracture | acetabular and pelvic fracture | Total | |
|---|---|---|---|---|---|
| Non-hip arthroplasty | 661,488 (99.57) | 2,499 (82.18) | 5,209 (92.72) | 601 (81.99) | 669,797 |
| Hip arthroplasty | 2,861 (0.43) | 542 (17.82) | 409 (7.28) | 132 (18.01) | 3,944 |
| Total | 664,349 | 3,041 | 5,618 | 733 | 673,741 |
Fig 2Cumulative incidence of hip arthroplasty of the three fracture groups and the control group.
Risk of hip arthroplasty between different 4 fracture group groups and normal group.
| Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
|---|---|---|---|---|
| 1.00 | - | - | ||
| 58.08 (52.76–63.95) | < .0001 | 58.42 (52.65–64.81) | < .0001 | |
| 22.42 (20.18–24.92) | < .0001 | 21.68 (19.35–24.28) | < .0001 | |
| 64.9 (54.01–78) | < .0001 | 62.04 (51.12–75.29) | < .0001 | |
| Age | 1.03 (1.02–1.03) | < .0001 | 1.03 (1.03–1.03) | < .0001 |
| Gender (Male vs. Female) | 1.5 (1.41–1.6) | < .0001 | 1.21 (1.13–1.29) | < .0001 |
| Comorbidities | ||||
| Myocardial infarct | 2.85 (1.53–5.33) | 0.001 | 0.7 (0.36–1.36) | 0.2872 |
| Congestive heart failure | 4.47 (3.36–5.95) | < .0001 | 1.21 (0.88–1.68) | 0.2471 |
| Peripheral vascular disease | 6.51 (4.27–9.93) | < .0001 | 1.09 (0.68–1.75) | 0.7311 |
| Cerebrovascular disease | 2.81 (2.24–3.52) | < .0001 | 0.91 (0.7–1.18) | 0.4629 |
| Dementia | 2.25 (0.94–5.41) | 0.0699 | 0.28 (0.11–0.71) | 0.0071 |
| Chronic lung disease | 4.08 (3.28–5.07) | < .0001 | 0.77 (0.6–0.99) | 0.0449 |
| Connective tissue disease | 12.4 (8.97–17.14) | < .0001 | 2.36 (1.6–3.5) | < .0001 |
| Ulcer | 5.57 (4.86–6.37) | < .0001 | 1.07 (0.91–1.25) | 0.4429 |
| Chronic liver disease | 6.59 (5.53–7.84) | < .0001 | 1.32 (1.07–1.63) | 0.0085 |
| Diabetes | 2.06 (1.81–2.35) | < .0001 | 0.9 (0.78–1.04) | 0.1555 |
| Diabetes with end organ damage | 3.63 (2.54–5.18) | < .0001 | 1.05 (0.69–1.61) | 0.8158 |
| Hemiplegia | 2.79 (1.68–4.65) | < .0001 | 0.7 (0.41–1.21) | 0.1987 |
| Moderate or severe kidney disease | 3.83 (3.06–4.78) | < .0001 | 0.86 (0.65–1.13) | 0.2765 |
| Malignant tumor | 1.41 (0.93–2.12) | 0.1042 | 0.54 (0.35–0.85) | 0.0076 |
| Leukemia, lymphoma | 1.06 (0.15–7.54) | 0.9541 | 0.53 (0.07–3.87) | 0.5335 |
| Moderate or severe liver disease | 2.98 (1.41–6.29) | 0.0042 | 1.12 (0.5–2.49) | 0.7817 |
| Metastasis | 1.03 (0.38–2.74) | 0.9589 | 0.46 (0.16–1.33) | 0.1488 |
HR: Hazard Ratio. ratio; CI, confidence interval; NA, not applicable due to few events.
Risk of hip arthroplasty between different 3 fracture group groups.
| Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
|---|---|---|---|---|
| 1.00 | - | - | ||
| 2.56 (2.25–2.91) | < .0001 | 2.59 (2.27–2.96) | < .0001 | |
| 2.72 (2.24–3.31) | < .0001 | 2.68 (2.2–3.27) | < .0001 | |
| Age | 1.02 (1.01–1.02) | < .0001 | 1.02 (1.02–1.02) | < .0001 |
| Gender (Male vs. Female) | 1.36 (1.18–1.56) | < .0001 | 1.21 (1.05–1.4) | 0.008 |
| Comorbidities | ||||
| Myocardial infarct | 1.11 (0.52–2.35) | 0.7885 | 0.78 (0.35–1.7) | 0.5231 |
| Congestive heart failure | 1.95 (1.39–2.73) | 0.0001 | 1.47 (1.01–2.13) | 0.042 |
| Peripheral vascular disease | 1.17 (0.71–1.94) | 0.5307 | 0.96 (0.57–1.62) | 0.8761 |
| Cerebrovascular disease | 1.29 (0.97–1.73) | 0.0809 | 1 (0.72–1.37) | 0.9783 |
| Dementia | 0.42 (0.15–1.12) | 0.0814 | 0.3 (0.11–0.83) | 0.0207 |
| Chronic lung disease | 1.33 (1.03–1.73) | 0.0311 | 0.85 (0.63–1.13) | 0.2577 |
| Connective tissue disease | 1.86 (1.2–2.88) | 0.0054 | 1.63 (1.04–2.57) | 0.0347 |
| Ulcer | 1.31 (1.12–1.54) | 0.0008 | 1.09 (0.91–1.3) | 0.3546 |
| Chronic liver disease | 1.38 (1.13–1.69) | 0.0017 | 1.15 (0.92–1.44) | 0.2065 |
| Diabetes | 1.48 (1.23–1.77) | < .0001 | 1.08 (0.87–1.34) | 0.4642 |
| Diabetes with end organ damage | 1.47 (0.99–2.19) | 0.0578 | 1.08 (0.67–1.76) | 0.7424 |
| Hemiplegia | 0.81 (0.46–1.43) | 0.4673 | 0.77 (0.43–1.38) | 0.377 |
| Moderate or severe kidney disease | 1.2 (0.92–1.56) | 0.1747 | 0.85 (0.62–1.16) | 0.3018 |